FDA Limits Duration and Usage of Samsca
The US Food and Drug Administration (FDA) has determined that the drug Samsca (tolvaptan) should not be used for longer than 30 days and should not be used in patients with underlying liver disease because it can cause liver injury, potentially requiring liver transplant or death.
Tolvaptan has Liver Injury Risk Says FDA
Otsuka and FDA notified healthcare professionals of significant liver injury associated with the use of Samsca.
At Last a Drug for Genetic Kidney Disease
Researchers have known about polycystic kidney disease for more than a century. However, they have had trouble coming up with an effective treatment for this common disease. That is, until now.